Stengone Carmine N.

CEO and President

Stengone Carmine N. has filed 6 SEC Form 4 filings (15 transaction rows) across 1 company, with disclosures dating back to 2026. 6 of those filings fall inside the rolling window. Most recent filing: Sep 8, 2026.

On the most recent filing, Stengone Carmine N. is listed as CEO and President at Contineum Therapeutics, Inc. Inside the rolling window, Stengone Carmine N. reported no open-market purchases and 7 open-market sales totaling $401K in CTNM. The largest disclosed transaction in the window is a sale of 10,000 CTNM shares on Jun 30, 2026, worth $160K.

Companies traded

Other insiders at CTNM

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$401K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
CTNMSale$41KSep 8SEC ↗
CTNMSale$40KAug 3SEC ↗
CTNMSale$40KJul 8SEC ↗
CTNMSale$160KJul 1SEC ↗
CTNMSale$70KFeb 26SEC ↗
CTNMSale$43KFeb 26SEC ↗
CTNMSale$6KFeb 13SEC ↗
Showing 1–7 of 7
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Stengone Carmine N. made?

Stengone Carmine N. has filed 6 SEC Form 4 filings (15 transaction rows) across 1 company since 2026.

Which companies does Stengone Carmine N. trade?

Stengone Carmine N. has filed SEC Form 4 disclosures for 1 company, including CTNM.

When was Stengone Carmine N.'s most recent SEC Form 4 filing?

Stengone Carmine N.'s most recent SEC Form 4 filing on Tracefour is dated Sep 8, 2026.

What is Stengone Carmine N.'s job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Stengone Carmine N. is listed as CEO and President.

What is Stengone Carmine N.'s total buy and sell value in the current window?

Inside the rolling retention window, Stengone Carmine N. bought $0 and sold $401K based on SEC Form 4 filings.

What was Stengone Carmine N.'s largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 10,000 CTNM shares on 2026-06-30, worth $160K, per SEC Form 4 filings.